Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Smoldering Multiple Myeloma
and you are
over 18
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: - Lenalidomide - Citarinostat (CC-96241) - PVX-410

Provided treatments

  • Drug: Hiltonol
  • Drug: Citarinostat
  • Drug: Lenalidomide
  • Biological: PVX-410
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02886065. The sponsor of the trial is Massachusetts General Hospital and it is looking for 20 volunteers for the current phase.
Official trial title:
A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma